Marginal Zone Lymphoma Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Suspended
- Follicular Lymphoma
- +4 more
- Obinutuzumab
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022I
Recruiting
- Follicular Lymphoma
- Marginal Zone Lymphoma
- tafasitamab
- +3 more
- Concord, California
- +153 more
2022-04-06
Apr 6, 2022U
Recruiting
- Non-Hodgkin Lymphoma
- +7 more
- Mosunetuzumab
- +2 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-03-28
Mar 28, 2022B
Not yet recruiting
- Follicular Lymphoma
- +2 more
- New Haven, Connecticut
- +2 more
2022-03-14
Mar 14, 2022C
Recruiting
- Marginal Zone Lymphoma
- Wien, Austria
- +19 more
2022-03-14
Mar 14, 2022Q
Recruiting
- Follicular Lymphoma
- +7 more
- Louisville, Kentucky
- +4 more
2022-03-11
Mar 11, 2022I
Recruiting
- Non-Hodgkin Lymphoma
- +4 more
- Duarte, California
- +12 more
2022-03-24
Mar 24, 2022U
Not yet recruiting
- Marginal Zone Lymphoma
- Loncastuximab tesirine 150 µg/Kg
- Loncastuximab tesirine 75µg/Kg
- (no location specified)
2022-03-15
Mar 15, 2022C
Recruiting
- Chronic Lymphocytic Leukemia
- +6 more
- Copanlisib
- Nivolumab
- Duarte, California
- +2 more
2022-03-09
Mar 9, 2022C
Active, not recruiting
- Adult Immunoblastic Lymphoma
- +12 more
- Cytology Specimen Collection Procedure
- Birmingham, Alabama
- +129 more
2022-03-23
Mar 23, 2022U
Active, not recruiting
- Non Hodgkin Lymphoma
- +8 more
- Miami, Florida
- +2 more
2022-03-08
Mar 8, 2022T
Active, not recruiting
- Diffuse Large B-Cell Lymphoma
- +4 more
- Ublituximab
- +2 more
- Birmingham, Alabama
- +167 more
2022-03-22
Mar 22, 2022B
Recruiting
- B-cell Malignancy
- +4 more
- Louisville, Kentucky
- +4 more
2022-03-22
Mar 22, 2022T
Recruiting
- CLL
- +9 more
- TG-1801
- Ublituximab
- Fayetteville, Arkansas
- +4 more
2022-03-22
Mar 22, 2022F
Recruiting
- Acute Biphenotypic Leukemia
- +18 more
- Cyclophosphamide
- +8 more
- Aurora, Colorado
- +2 more
2022-03-02
Mar 2, 2022J
Not yet recruiting
- B-Cell Lymphoma
- +8 more
- Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
- Pittsburgh, PennsylvaniaAHN Cancer Institute - West Penn Hospital
2022-03-08
Mar 8, 2022C
Recruiting
- Marginal Zone Lymphoma
- Bochum, Germany
- +15 more
2022-03-14
Mar 14, 2022A
Active, not recruiting
- Lymphoma, B-Cell
- +8 more
- Scottsdale, Arizona
- +9 more
2022-03-10
Mar 10, 2022M
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Recruiting
- Follicular Lymphoma (FL)
- +2 more
- Zandelisib
- +3 more
- Tucson, Arizona
- +97 more
2022-03-10
Mar 10, 2022M
Recruiting
- Marginal Zone Lymphoma
- Duarte, California
- +7 more
2022-03-09
Mar 9, 2022M
Recruiting
- Marginal Zone Lymphoma
- Ibrutinib
- +2 more
- Los Angeles, California
- +12 more
2022-03-09
Mar 9, 2022B
Recruiting
- Mantle Cell Lymphoma
- +9 more
- L-Bcl-2 antisense oligonucleotide
- Augusta, Georgia
- +2 more
2022-03-08
Mar 8, 2022M
Recruiting
- Follicular Lymphoma (FL)
- +2 more
- Zandelisib (ME-401)
- Tucson, Arizona
- +115 more
2022-03-08
Mar 8, 2022U
Recruiting
- Marginal Zone Lymphoma
- Graz, Austria
- +10 more
2022-03-07
Mar 7, 2022J
Active, not recruiting
- Follicular Lymphoma
- +3 more
- Vitamin D
- +2 more
- Miami, Florida
- +6 more
2022-03-06
Mar 6, 2022